David A. Siegel Autolus Therapeutics PLC Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Two Sigma Advisers, LP holds 256,700 shares of AUTL stock, worth $931,821. This represents 0.0% of its overall portfolio holdings.
Number of Shares
256,700
Previous 31,100
725.4%
Holding current value
$931,821
Previous $198,000
351.01%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding AUTL
# of Institutions
114Shares Held
167MCall Options Held
34.2KPut Options Held
19.5K-
Syncona Portfolio LTD Guernsey, Channel Islands, X021.3MShares$77.5 Million86.45% of portfolio
-
Blackstone Inc New York, NY20.5MShares$74.4 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA17.9MShares$64.9 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT15.3MShares$55.4 Million1.74% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.3MShares$44.8 Million0.59% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $330M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...